Login to Your Account



Eisai Pledges $200M to Oncology Start-up H3

By BioWorld Today Staff Reports


Monday, January 31, 2011
Eisai Inc., of Woodcliff Lake, N.J., the U.S. pharmaceutical operation of Tokyo-based Eisai Co. Ltd., has pledged as much as $200 million in research funding to start-up H3 Biomedicine, of Cambridge, Mass., which hopes to develop oncology treatments genetically tailored to patients' cancers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription